These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11977556)

  • 1. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
    Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
    Hehl EM
    Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.